Literature DB >> 34150147

The effect of pantoprazole and somatostatin combined with thrombin in the treatment of non-esophagogastric varicosity upper gastrointestinal bleeding.

Yu Duan1, Ji Chen1, Hong Cui1, Cuijuan Zhao1.   

Abstract

OBJECTIVE: To explore the effect of pantoprazole and somatostatin combined with thrombin in the treatment of non-esophagogastric varicosity upper gastrointestinal bleeding (UGB) as well as its influence on serum hs-CRP and coagulation function.
METHODS: From June 2016 to May 2018, patients with upper gastrointestinal hemorrhage due to non-esophagogastric varices in our hospital were selected as research subjects. After screening, they were randomly divided into the combined group (57 cases) and the control group (57 cases). After the two groups are treated, the therapeutic effect was observed. The two groups of patients were followed up for 6 consecutive months, and the data were statistically analyzed.
RESULTS: It was found that there wass no significant difference between the two groups in gender, age, amount of bleeding, and etiology (P > 0.05). It was found that the immediate hemostasis rate and the hemostasis rate within 24 hours in the combined group were distinctly higher compared to the control group. The difference has statistical significance (P < 0.05). The total effective rate of the combined group was distinctly higher compared to the control group (P < 0.05). By comparing the expression levels of hs-CRP and IL-6 protein in the serum of the two groups before and after treatment, it was found that there was no significant difference in the expression levels of hs-CRP and IL-6 protein before treatment. However, after treatment, it was found that the levels of hs-CRP and IL-6 protein in the combined group were distinctly lower compared to the control group (P < 0.05). By analyzing adverse reactions, it was found that the combined group had distinctly lower adverse reactions compared to the control group (P < 0.05).
CONCLUSION: This work provides an experimental basis for the diagnosis and treatment of non-esophagogastric varicose UGB in the clinic. AJTR
Copyright © 2021.

Entities:  

Keywords:  Pantoprazole; hs-CRP; somatostatin; thrombin; upper gastrointestinal hemorrhage

Year:  2021        PMID: 34150147      PMCID: PMC8205661     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  21 in total

1.  Pantoprazole or Placebo for Stress Ulcer Prophylaxis (POP-UP): Randomized Double-Blind Exploratory Study.

Authors:  Shane P Selvanderan; Matthew J Summers; Mark E Finnis; Mark P Plummer; Yasmine Ali Abdelhamid; Michael B Anderson; Marianne J Chapman; Christopher K Rayner; Adam M Deane
Journal:  Crit Care Med       Date:  2016-10       Impact factor: 7.598

2.  A new pollen-derived microcarrier for pantoprazole delivery.

Authors:  Lalehan Akyuz; Idris Sargin; Murat Kaya; Talip Ceter; Ilgaz Akata
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2016-11-04       Impact factor: 7.328

3.  Multifocal gastrointestinal varices: a rare manifestation of immunoglobulin G4-related disease.

Authors:  Tien-Ching Lin; Wei-Lun Chang
Journal:  Postgrad Med       Date:  2019-01-29       Impact factor: 3.840

4.  High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial.

Authors:  David A Bush; Donald J Hillebrand; James M Slater; Jerry D Slater
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

Review 5.  What Does Lesion Blood Flow Tell Us About Risk Stratification and Successful Management of Non-variceal UGI Bleeding?

Authors:  Kevin A Ghassemi; Dennis M Jensen
Journal:  Curr Gastroenterol Rep       Date:  2017-04

6.  Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Authors:  Aaron R Hansen; Ian F Tannock; Arnoud Templeton; Eric Chen; Andrew Evans; Jennifer Knox; Amy Prawira; Srikala S Sridhar; Susie Tan; Francisco Vera-Badillo; Lisa Wang; Bradly G Wouters; Anthony M Joshua
Journal:  Oncologist       Date:  2019-04-05

7.  Withholding Pantoprazole for Stress Ulcer Prophylaxis in Critically Ill Patients: A Pilot Randomized Clinical Trial and Meta-Analysis.

Authors:  Waleed Alhazzani; Gordon Guyatt; Mohammed Alshahrani; Adam M Deane; John C Marshall; Richard Hall; John Muscedere; Shane W English; François Lauzier; Lehana Thabane; Yaseen M Arabi; Tim Karachi; Bram Rochwerg; Simon Finfer; Nick Daneman; Fayez Alshamsi; Nicole Zytaruk; Diane Heel-Ansdell; Deborah Cook
Journal:  Crit Care Med       Date:  2017-07       Impact factor: 7.598

Review 8.  Emerging Endoscopic Treatments for Nonvariceal Upper Gastrointestinal Hemorrhage.

Authors:  Alvaro Martínez-Alcalá; Klaus Mönkemüller
Journal:  Gastrointest Endosc Clin N Am       Date:  2018-04-12

9.  Gastrointestinal complications in critically ill patients: the intensivists' overview.

Authors:  J E Gottlieb; P I Menashe; E Cruz
Journal:  Am J Gastroenterol       Date:  1986-04       Impact factor: 10.864

10.  Comparison of risk scoring systems for patients presenting with upper gastrointestinal bleeding: international multicentre prospective study.

Authors:  Adrian J Stanley; Loren Laine; Harry R Dalton; Jing H Ngu; Michael Schultz; Roseta Abazi; Liam Zakko; Susan Thornton; Kelly Wilkinson; Cristopher J L Khor; Iain A Murray; Stig B Laursen
Journal:  BMJ       Date:  2017-01-04
View more
  2 in total

1.  Somatostatin plus Gastroscopic Administration of Omeprazole for the Treatment of Acute Upper Gastrointestinal Bleeding: An Exploration of a Promising Alternative.

Authors:  Lu Feng; Jing Fu
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-04       Impact factor: 2.650

2.  Intravenous Drip of Somatostatin Followed by Restricted Fluid Resuscitation to Treat Upper Gastrointestinal Bleeding in Patients with Liver Cirrhosis.

Authors:  Xuni He; Zhuhua Dai; Peina Shi; Jiemin Hong
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-13       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.